glofitamab
Selected indexed studies
- Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. (Lancet, 2024) [PMID:39550172]
- Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (N Engl J Med, 2022) [PMID:36507690]
- Glofitamab: First Approval. (Drugs, 2023) [PMID:37285013]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Glofitamab with Polatuzumab Vedotin in Refractory Burkitt's Lymphoma. (2025) pubmed
- Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. (2024) pubmed
- Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (2022) pubmed
- Glofitamab: First Approval. (2023) pubmed
- Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study. (2025) pubmed
- Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. (2021) pubmed
- Glofitamab. (2006) pubmed
- Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. (2022) pubmed
- Glofitamab CD20-TCB bispecific antibody. (2021) pubmed
- Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab. (2022) pubmed